No headlines found.
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Globe Newswire (Tue, 2-Jun 8:00 AM ET)
Globe Newswire (Tue, 28-Apr 8:00 AM ET)
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Globe Newswire (Wed, 8-Apr 8:00 AM ET)
Globe Newswire (Thu, 26-Mar 8:00 AM ET)
Globe Newswire (Tue, 17-Mar 8:00 AM ET)
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Globe Newswire (Tue, 10-Mar 8:00 AM ET)
Globe Newswire (Mon, 9-Mar 8:00 AM ET)
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Daxor - Closed End trades on the NASDAQ stock market under the symbol DXR.
As of June 3, 2026, DXR stock price climbed to $10.73 with 422 million shares trading.
DXR has a market cap of $62.53 million. This is considered a Micro Cap stock.
In the last 3 years, DXR traded as high as $14.76 and as low as $6.55.
The top ETF exchange traded funds that DXR belongs to (by Net Assets): VTI.
DXR has underperformed the market in the last year with a price return of +24.3% while the SPY ETF gained +27.8%. DXR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.9% and -5.5%, respectively, while the SPY returned +11.1% and +1.8%, respectively.
DXR support price is $9.49 and resistance is $11.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXR shares will trade within this expected range on the day.